Microba Life Sciences Limited has signed a strategic partnership agreement with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.
Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based on their microbiome test results, leveraging the recommendations from Microba’s Analysis Platform.
This personalised, pharmacy-integrated service model – delivered with trained, registered pharmacists – will bring a level of science and personalisation to an industry which commonly provides customers with one-size-fits-all solutions.
Midnight Health CEO, Nic Blair said: “We are experiencing strong demand for innovative online healthcare solutions aligned to an individual needs. We already have more than 13,000 subscribers across our existing brands with strong month-on-month growth. Many of our customers are looking for gut health solutions and we are proud to bring the Vidality product to our customers in partnership with Microba”.
The Agreement was signed, for an initial period of 3 years, after a successful pilot which tested the service model and product offering. It further demonstrates Microba’s scalable technology and ability to deliver evidence-based gut health solutions together with distribution partners.
Commenting on the partnership, Microba CEO, Dr Luke Reid said:
“Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology.”Dr Luke Reid, CEO at Microba
This delivers on an undertaking in the Company’s Prospectus to enter into an Australian partnership with a fast-growth innovative consumer healthcare company.